Biology subjects

Mottaqi, M.

Publications and source records attributed to Mottaqi, M..

5 recordsLinked to original sources

bioRxiv2026

GEM-GPT Enables Personalized Cell Type-Resolved Therapeutic Design for Systems Pharmacology

Generative AI is transforming drug discovery, yet most approaches follow one-drug-one-target paradigms ill-suited to the heterogeneity of chronic, systemic diseases. Systems pharmacology offers an alternative, but generative tools designed for it remain scarce. We introduce GEM-GPT, a transcriptomics-guided framework that generates personalized therapeutic candidate molecules intended to shift cell type-specific disease states toward healthy phenotypes. GEM-GPT uses a biology-inspired deep fusion architecture that couples a single-cell RNA-sequencing foundation model with a molecular GPT, modeling cell type-specific chemical-gene interactions throughout molecule generation rather than through fixed conditioning. Across bulk and single-cell chemical perturbations and CRISPR knock-out signatures, GEM-GPT outperforms state-of-the-art baselines, produces cell type-resolved molecules, and generalizes to unseen cellular contexts. In a case study on opioid use disorder (OUD), it generates novel candidates, recovers FDA-approved OUD-related drugs absent from training, and yields predicted binders to OUD-related targets. GEM-GPT bridges single-cell omics and molecular generation for personalized, cell-type-resolved, systems-aware therapeutic design.

pharmacology and toxicology↗

bioRxiv2026

A Scalable Sign-Aware Multi-Omics Knowledge Graph Foundation Model for Mechanistic Drug Action and Clinical Response Predictions

Mechanistically predicting drug action requires distinguishing activating from inhibitory interactions across broad chemical space, yet most biomedical knowledge graphs and graph neural networks (GNNs) rely on unsigned associations that obscure regulatory logic and have a limited chemical coverage. Here we present SIGMA-KG (SIGned Multi-omics Atlas Knowledge Graph) and FLASH (Fast Lightweight Architecture for Signed Heterogeneous GNN), a graph foundation model pretrained through self-supervised learning on SIGMA-KG. SIGMA-KG integrates chemogenomic perturbation, transcriptomic, proteomic, and clinical data while explicitly encoding biological polarity and directionality. FLASH preserves polarity composition across multi-hop pathways through structural balance principles, enabling scalable mechanistic reasoning. Without task-specific fine-tuning, FLASH consistently outperforms or matches nine state-of-the-art unsigned, relational, and signed graph baselines across drug mode-of-action prediction, clinical response modeling, and drug-drug interaction prediction, while substantially improving computational efficiency. FLASH further enables explainable inductive drug repurposing, achieving a 69.6% external clinical validation success rate across four complex diseases.

systems biology↗

bioRxiv2026

DrugPTM-Bench: A Large-Scale Dataset for Predictive Modeling of Drug-Induced Cell Type-Specific Protein Post-Translational Modifications

Protein post-translational modifications (PTMs), particularly phosphorylation, serve as the primary "molecular switches" that orchestrate cellular signaling and drug response. While PTM dysregulation is a hallmark of cancer and neurodegeneration, the lack of standardized, drug-perturbed datasets has hindered the development of predictive models capable of capturing context-dependent PTM responses. Effective predictive modeling must therefore integrate multidimensional data, including the specific drug, dosage, treatment duration, cellular background, and the modified site. However, existing PTM resources remain largely static and fail to capture drug-induced regulation across these critical dimensions. To address this gap, we present DrugPTM-Bench, a curated, large-scale benchmark derived from decryptM-derived dose-dependent PTM measurements, standardizing site-level drug response across 7 cancer cell lines, 27 drugs, and 11,167 proteins. Comprising 99.5% phosphorylation events, the dataset includes six time points, 16 dosage levels, and pEC50 potency values (half-maximal effective concentration). We formulate a classification task to identify upregulated, downregulated, or unchanged PTM sites (following a drug treatment), a critical step in deciphering drug Mechanism of Action (MoA) and target engagement. Our evaluation reveals that in protein-disjoint out-of-distribution (OOD) setting, baseline machine learning and deep learning models struggle to recover minority regulation classes, while standard rebalancing strategies improve recall only at the cost of precision and overall F1-score. These results indicate that current methods do not learn robust decision boundaries between regulated and unchanged PTM events. DrugPTM-Bench provides a phosphoproteomics benchmark for modeling drug-induced PTM regulation in imbalanced biological settings. Beyond classification, DrugPTM-Benchs retention of pEC50 values, drug perturbation profiles, and site-level sequence context enables additional predictive tasks including drug potency regression, mechanism-of-action prediction from PTM fingerprints, and drug-specific PTM site sensitivity ranking, establishing a multi-task benchmark for PTM-centric drug discovery. Ultimately, DrugPTM-Bench establishes a rigorous framework for developing robust, context-aware models to elucidate drug MoA and signaling dynamics.

systems biology↗

bioRxiv2025

Integrating Interpretable Machine Learning and Multi-omics Systems Biology for Personalized Biomarker Discovery and Drug Repurposing in Alzheimer's Disease

Alzheimers disease (AD) is characterized by region- and patient-specific molecular heterogeneity, which hinders therapeutic design. In this study, we introduce PRISM-ML (PRecision-medicine using Interpretable Systems and Multiomics with Machine Learning), an open-source integrated analysis pipeline that combines interpretable machine learning with systems biology and electronic health record (EHR) data mining to elucidate the molecular diversity of AD and predict promising drug repurposing opportunities. First, we integrated and harmonized transcriptomic (bulk RNA-seq) and genomic (genome-wide association study) data from 2105 brain samples, each with matched data from the same individual (1363 AD patients, 742 controls; nine tissues), sourced from three independent studies. Random forest classifiers with SHapley Additive exPlanations (SHAP) identified patient-specific biomarkers; unsupervised clustering resolved 36 molecularly distinct "subtissues" (clusters of samples); and gene-gene co-expression networks prioritized 262 high-centrality bottleneck genes as putative regulators of dysregulated pathways. Next, knowledge graph-based drug repurposing predicted six FDA-approved drugs that simultaneously target multiple bottleneck genes and multiple AD-relevant pathways. Notably, in a large U.S. de-identified insurance-claims database (n = 364733), exposure to promethazine, one of the candidate drugs, was associated with a 57-62 % lower incidence of AD versus an active antihistamine comparator (adjusted hazard ratio 0.38; inverse-probability weighted 0.43; both p < 0.001), providing real-world support for its repurposing potential. In summary, PRISM-ML, as an explainable multi-omics analysis pipeline, is readily transferable to other complex diseases, advancing precision medicine.

systems biology↗

bioRxiv2025

MolGene-E: Inverse Molecular Design to Modulate Single Cell Transcriptomics

Designing drugs that can restore a diseased cell to its healthy state is an emerging approach in systems pharmacology to address medical needs that conventional target-based drug discovery paradigms have failed to meet. Single-cell transcriptomics can comprehensively map the differences between diseased and healthy cellular states, making it a valuable technique for systems pharmacology. However, single-cell omics data is noisy, heterogeneous, scarce, and high-dimensional. As a result, no machine learning methods currently exist to use single-cell omics data to design new drug molecules. We have developed a new deep generative framework named MolGene-E to tackle this challenge. MolGene-E combines two novel models: 1) a cross-modal model that can harmonize and denoise chemical-perturbed bulk and single-cell transcriptomics data, and 2) a contrastive learning-based generative model that can generate new molecules based on the transcriptomics data. MolGene-E consistently outper-forms baseline methods in generating high-quality, hit-like molecules on gene expression profiles from two evaluation settings: CRISPR knock-out perturbation profiles from L1000toRNAseq dataset, and single-cell gene expression profiles from Sciplex-3 dataset, both in zero-shot molecule generation setting. This superior performance is demonstrated across diverse de novo molecule generation metrics. Extensive evaluations demonstrate that MolGene-E achieves state-of-the-art performance for zero-shot molecular generations. This makes MolGene-E a potentially powerful new tool for drug discovery.

bioinformatics↗